1) Knochenhauer ES, Key TJ, Kahsar─Miller M, et al : Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States : a prospective study. J Clin Endocrinol Metab 83 : 3078─3082, 1998
2) Farah L, Lazenby AJ, Boots LR, et al : Prevalence of polycystic ovary syndrome in women seeking treatment from community electrologists. Alabama Professional Electrology Association Study Group. J Reprod Med 44 : 870─874, 1999
3) Diamanti─Kandarakis E, Kouli CR, Bergiele AT, et al : A survey of the polycystic ovary syndrome in the Greek island of Lesbos : hormonal and metabolic profile. J Clin Endocrinol Metab 84 : 4006─4011, 1999
4) Venn A, Shelly J : Should there be long─term monitoring of women with polycystic ovary syndrome?. In : Polycystic Ovary Syndrome(Kovacs, GT ed), pp202─217, Cambridge University Press, UK, 2000
5) 高倉賢二 : 多嚢胞卵巣症候群─最近の話題.産婦の進歩50 : 208─213, 1998
6) 高倉賢二,中村光彰,藤井信吾 : 多嚢胞卵巣症候群日本臨床 : 59(増刊号8本邦臨床統計集(2)): 184─190, 2001
7) Stein IF, Leventhal ML : Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 29 : 181─191, 1935
8) Hacihanefioglu B : Polycystic ovary syndrome nomenclature : chaos? Fertil Steril 73 : 1261─1262, 2000
9) Ehrmann DA, et al : Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med 327 : 157─162, 1992
10) 日産婦生殖・内分泌委員会 : 本邦婦人における多嚢胞性卵巣症候群の診断基準設定に関する小委員会(平成2年度~平成4年度)検討結果報告.日産婦誌45 : 1359─1367, 1993
11) Hershlag A, Peterson CM : Endocrine disorders. In : Novak's Gynecology, 12th ed(Berek JS, et al eds). pp837─886, Williams & Wilkins, Baltimore, 1996
12) Zawadzki JK, Dunaif A : Diagnostic criteria for polycystic ovary syndrome : towards a rational approach. In : Polycystic ovary syndrome(Dunaif A, Givens JR, Haseltine F, et al eds). pp377─384, Blackwell, Boston, 1992
14) Quigley ME, Rakoff JS, Yen SS : Increased luteinizing hormone sensitivity to dopamine inhibition in polycystic ovary syndrome. J Clin Endocrinol Metab 52 : 231─234, 1981
14) 高倉賢二,泰井俊造,森 崇英 : ブロモクリプチン療法により高LH血症の増悪した多嚢胞卵巣症候群の1例.代謝24 : 1133─1139, 1987
15) Takakura K, Taii S, Ihara Y, et al : Aggravation of inappropriate luteinizing hormone secretion by bromocriptine in polycystic ovary syndrome with elevated serum dehydroepiandrosterone sulfate. Endocrinol Japon(Endocr J)36 : 261─268, 1989
16) Yen SSC, Chaney C, Judd HL : Functional aberrations of the hypothalamic─pituitary system in polycystic ovary syndrome : a consideration of the pathogenesis. In : The endocrine function of the human ovary(James VHT, Serio M, Giusti G, eds), pp373─385, Academic Press, New York, USA, 1976
17) Chang RJ : Polycystic ovary syndrome and hyperandrogenic states. In : Yen and Jaffe's Reproductive endocrinology, 5th ed(Strauss III JF, Barbieri RL eds). pp597─632, Elsvier, Philadelphia, USA, 2004
18) Poretsky L, Piper B : Insulin resistance, hypersecretion of LH, and a dual─defect hypothesis for the pathogenesis of polycystic ovary syndrome. Obstet Gynecol 84 : 613─621, 1994
19) Giudice LC : Insulin─like growth factors and ovarian follicular development. Endocr Rev 13 : 641─669, 1992
20) Mori T, Takakura K, Fujiwara H, et al : Immunology of ovarian function. In : Reproductive Immunology(Bronson RA, Alexander NJ, Anderson D, et al eds). Blackwell Science, Cambridge, pp240─274, 1996
21) Poretsky L, Cataldo NA, Rosenwaks Z, et al : The insulin─related ovarian regulatory system in health and disease. Endocr Rev 20 : 535─582, 1999
22) Burghen GA, Givens JR, Kitabchi AE : Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 50 : 113─116, 1980
23) Dunaif A, Segal KR, Futterweit W, et al : Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38 : 1165─1174, 1989
24) Ovalle F, Azziz R : Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 77 : 1095─1105, 2002
25) De Leo V, La Marca A, Petraglia F : Insulin─lowering agents in the management of polycystic ovary syndrome. Endocr Rev 24 : 633─667, 2003
26) Lord JM, Flight IH, Norman RJ : Insulin─sensitising drugs(metformin, troglitazone, rosiglitazone, pioglitazone, D─chiro─inositol)for polycystic ovary syndrome. Cochrane Database Syst Rev. Issue 3 : CD003053, 2003